Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
作者信息
Hopcroft Lorna, Wigmore Eleanor M, Williamson Stuart C, Ros Susana, Eberlein Cath, Moss Jennifer I, Urosevic Jelena, Carnevalli Larissa S, Talbot Sara, Bradshaw Lauren, Blaker Catherine, Gunda Sreeharsha, Owenson Venetia, Hoffmann Scott, Sutton Daniel, Jones Stewart, Goodwin Richard J A, Willis Brandon S, Rooney Claire, DeBruin Elza, Barry Simon T
机构信息
Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK.
出版信息
NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6.
Abstract
摘要
相似文献
1
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.作者更正：在帕博西尼耐药的雌激素受体阳性乳腺癌临床前模型中，联合使用AKT抑制剂卡匹西利布和选择性雌激素受体降解剂氟维司群是有效的。
NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6.
2
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.在对哌柏西利耐药的雌激素受体阳性（ER+）乳腺癌临床前模型中，联合使用AKT抑制剂卡哌西利布和选择性雌激素受体降解剂（SERD）氟维司群是有效的。
NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w.
3
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.作者更正：在帕博西尼耐药的ER+乳腺癌临床前模型中，联合使用AKT抑制剂卡匹西利布和SERD氟维司群有效。
NPJ Breast Cancer. 2023 Sep 19;9(1):76. doi: 10.1038/s41523-023-00581-8.
4
"The emerging role of capivasertib in breast cancer".卡培他滨在乳腺癌中的新作用。
Breast. 2022 Jun;63:157-167. doi: 10.1016/j.breast.2022.03.018. Epub 2022 Apr 1.
5
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.SERD/SERM 杂交 CDK4/6 抑制剂组合在内分泌治疗抵抗性乳腺癌模型中的疗效
Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.
6
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.在携带雌激素受体（ER）突变的临床前内分泌抵抗性乳腺癌模型中的有效联合治疗方法。
Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.
7
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.在乳腺癌的临床前模型中对氟维司群的药代动力学和药效学分析，以评估其雌激素受体-α降解剂活性在抗肿瘤疗效中的重要性。
Breast Cancer Res Treat. 2020 Jan;179(1):67-77. doi: 10.1007/s10549-019-05454-y. Epub 2019 Sep 27.
8
A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.丹麦一项回顾性、非干预性研究，纳入了接受哌柏西利治疗的 ER+/HER2 阴性、局部晚期或转移性乳腺癌患者。
Acta Oncol. 2023 Mar;62(3):290-297. doi: 10.1080/0284186X.2023.2194030. Epub 2023 Apr 3.
9
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.选择性AKT激酶抑制剂卡匹西利与氟维司群联合用于PTEN突变的雌激素受体阳性转移性乳腺癌
NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7.
10
Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.哌柏西利联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期/转移性乳腺癌日本患者的疗效和安全性。
In Vivo. 2019 Nov-Dec;33(6):2037-2044. doi: 10.21873/invivo.11701.
Zotero 插件